What is Integrated Biopharma Book Value per Share?
Integrated Biopharma's book value per share for the quarter that ended in Mar. 2024 was $0.63.
During the past 12 months, Integrated Biopharma's average Book Value Per Share Growth Rate was 0.30% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 45.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Integrated Biopharma was 113.20% per year. The lowest was -59.70% per year. And the median was 3.20% per year.
During the past 13 years, the highest P/B Ratio of Integrated Biopharma was 21.43. The lowest was 0.30. And the median was 2.15.
Integrated Biopharma Book Value per Share Historical Data
The historical data trend for Integrated Biopharma's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Integrated Biopharma's Book Value per Share
For the Packaged Foods subindustry, Integrated Biopharma's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Integrated Biopharma's PB Ratio Distribution in the Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Integrated Biopharma's PB Ratio distribution charts can be found below:
* The bar in red indicates where Integrated Biopharma's PB Ratio falls into.
Integrated Biopharma Book Value per Share Calculation
Integrated Biopharma's Book Value Per Share for the fiscal year that ended in Jun. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.
Integrated Biopharma (OTCPK:INBP) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Integrated Biopharma Book Value per Share Related Terms
Thank you for viewing the detailed overview of Integrated Biopharma's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Integrated Biopharma (Integrated Biopharma) Business Description
Integrated Biopharma Inc is a pharmaceutical company engaged in manufacturing, distributing, marketing, and selling vitamins, nutritional supplements, and herbal products. It operates in two segments; Contract Manufacturing and Other Nutraceutical Businesses. It serves the needs of the nutraceutical industry by directly doing business as Chem International Inc. and through its operating subsidiaries; Manhattan Drug Company, Inc., AgroLabs, Inc., IHT Health Products, Inc. and MDC Warehousing and Distribution, Inc. The company generates maximum revenue from the Contract Manufacturing segment. The business operates and generates the majority of revenue from the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
INBP has been successfully added to your 